Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.
Tag Archive for: financing
French-US-based investment specialist Lauxera Capital Partners announced today that it has invested €17m in Swedish cell culture company BioLamina AB (BioLamina)
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against endemic outbreaks.
Mysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune indications. The focus is on pan-PIM kinase inhibitors that uniquely modulate multilineage immune cell functions.
Women’s health specialist Mithra Pharmaceuticals SA has entered into a definitive agreement to raise €20m in gross proceeds via a private placement of 10 million new ordinary shares with Armistice Capital.
French vaccine maker Valneva SE will double the amount of a US$100m debt financing granted by Deerfield Management Company and OrbiMed.
Swiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.
British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.
In an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.
Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.